Literature DB >> 27104300

CDK1/2 toolbox in need of an upgrade.

Anisha Kothari1, Timothy C Chambers1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27104300      PMCID： PMC4957594          DOI： 10.1080/15384101.2016.1176399

Source DB:  PubMed          Journal:  Cell Cycle        ISSN： 1551-4005            Impact factor:   4.534


× No keyword cloud information.
  7 in total

1.  Multisite phosphorylation by Cdk2 and GSK3 controls cyclin E degradation.

Authors:  Markus Welcker; Jeffrey Singer; Keith R Loeb; Jonathan Grim; Andrew Bloecher; Mark Gurien-West; Bruce E Clurman; James M Roberts
Journal:  Mol Cell       Date:  2003-08       Impact factor: 17.970

Review 2.  Cdks, cyclins and CKIs: roles beyond cell cycle regulation.

Authors:  Shuhui Lim; Philipp Kaldis
Journal:  Development       Date:  2013-08       Impact factor: 6.868

Review 3.  The history and future of targeting cyclin-dependent kinases in cancer therapy.

Authors:  Uzma Asghar; Agnieszka K Witkiewicz; Nicholas C Turner; Erik S Knudsen
Journal:  Nat Rev Drug Discov       Date:  2015-02       Impact factor: 84.694

Review 4.  Critical reanalysis of the methods that discriminate the activity of CDK2 from CDK1.

Authors:  Nandini Sakurikar; Alan Eastman
Journal:  Cell Cycle       Date:  2016-03-17       Impact factor: 4.534

Review 5.  Cell cycle, CDKs and cancer: a changing paradigm.

Authors:  Marcos Malumbres; Mariano Barbacid
Journal:  Nat Rev Cancer       Date:  2009-03       Impact factor: 60.716

6.  Transgenic cyclin E triggers dysplasia and multiple pulmonary adenocarcinomas.

Authors:  Yan Ma; Steven Fiering; Candice Black; Xi Liu; Ziqiang Yuan; Vincent A Memoli; David J Robbins; Heather A Bentley; Gregory J Tsongalis; Eugene Demidenko; Sarah J Freemantle; Ethan Dmitrovsky
Journal:  Proc Natl Acad Sci U S A       Date:  2007-02-27       Impact factor: 11.205

7.  A subset of cancer cell lines is acutely sensitive to the Chk1 inhibitor MK-8776 as monotherapy due to CDK2 activation in S phase.

Authors:  Nandini Sakurikar; Ruth Thompson; Ryan Montano; Alan Eastman
Journal:  Oncotarget       Date:  2016-01-12
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.